“Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor. Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the audience at the 10^th Conference on Aging Research and Drug Development in Copenhagen on Monday. “Hence the need for … surrogate markers.” And “we are not there … we are actually quite far from there.”

Cryptosporidiosis is a parasitic infection caused by Cryptosporidium where infected individuals develop profuse watery diarrhea and enteric symptoms such as abdominal pain. In immunocompromised or malnourished children, the infection may become chronic and lead to significant morbidity and mortality rates.

Viral proteases are well-established therapeutic targets in HIV and hepatitis C virus infections. Following the recent COVID-19 pandemic, one of the strategies in place is SARS-CoV-2 main protease (Mpro) inhibition, given the crucial role of SARS-CoV-2 Mpro in the replication of the virus.

“I am not a fortune teller, nor am I a gambler. I will make no bets,” Lorraine Kalia told the audience at the 2023 International Congress of Parkinson’s Disease and Movement Disorders. “But I am optimistic.” At the meeting, which is being held in Copenhagen this week, Kalia, who is a scientist at Toronto Western Hospital’s Krembil Brain Institute and at the University of Toronto’s Tanz Centre for Research in Neurodegenerative Diseases, was giving an overview of “Emerging targets in the clinic” in a plenary session on “Therapeutic strategies for the future.”

Microtubule-associated serine/threonine kinase-like (MASTL) is involved in cell proliferation, migration, and invasion and for that reason is considered a relevant therapeutic target for cancer treatment. At the recent ACS Fall meeting, researchers from Pfizer Inc. presented the discovery and characterization of a series of potent and selective MASTL inhibitors for the treatment of cancer.

New treatment options are needed for the prevention of relapse to alcohol use, the major problem in the treatment of alcohol dependence in humans. The neuropeptide relaxin-3/RXFP3 plays a relevant role in the motivation for the reward process and is considered a possible therapeutic target in addictive behaviors.

Voltage-gated potassium channels (KCNQ) control neural excitability and their dysfunction leads to neuronal channelopathies frequently related to...

Protease form factor Xia (FXIa) is a therapeutic target for thrombosis prevention due to its well-known contribution to VTE and ischemic stroke in humans. Researchers from Janssen Pharmaceutica NV presented an antithrombotic target FXIa inhibitor obtained through a non-classical interactions strategy to improve the pharmacokinetic and pharmacological activity for the treatment of thrombosis. In the series, the potency was increased by using water-mediated hydrogen bonds to reduce polar hydrogen bond donors and using methyl to displace high-energy waters.